269 related articles for article (PubMed ID: 17403718)
1. Modulation of nucleosome dynamics in Huntington's disease.
Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease.
Ferrante RJ; Ryu H; Kubilus JK; D'Mello S; Sugars KL; Lee J; Lu P; Smith K; Browne S; Beal MF; Kristal BS; Stavrovskaya IG; Hewett S; Rubinsztein DC; Langley B; Ratan RR
J Neurosci; 2004 Nov; 24(46):10335-42. PubMed ID: 15548647
[TBL] [Abstract][Full Text] [Related]
3. Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes.
Guiretti D; Sempere A; Lopez-Atalaya JP; Ferrer-Montiel A; Barco A; Valor LM
Neurobiol Dis; 2016 May; 89():190-201. PubMed ID: 26851501
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
[TBL] [Abstract][Full Text] [Related]
5. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
6. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.
Ryu H; Lee J; Hagerty SW; Soh BY; McAlpin SE; Cormier KA; Smith KM; Ferrante RJ
Proc Natl Acad Sci U S A; 2006 Dec; 103(50):19176-81. PubMed ID: 17142323
[TBL] [Abstract][Full Text] [Related]
7. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
8. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models.
Sadri-Vakili G; Bouzou B; Benn CL; Kim MO; Chawla P; Overland RP; Glajch KE; Xia E; Qiu Z; Hersch SM; Clark TW; Yohrling GJ; Cha JH
Hum Mol Genet; 2007 Jun; 16(11):1293-306. PubMed ID: 17409194
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
Wang F; Fischhaber PL; Guo C; Tang TS
Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
[TBL] [Abstract][Full Text] [Related]
10. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.
Moreno CL; Ehrlich ME; Mobbs CV
Neurobiol Dis; 2016 Jan; 85():25-34. PubMed ID: 26485309
[TBL] [Abstract][Full Text] [Related]
11. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice.
Zajac MS; Pang TY; Wong N; Weinrich B; Leang LS; Craig JM; Saffery R; Hannan AJ
Hippocampus; 2010 May; 20(5):621-36. PubMed ID: 19499586
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics of Huntington's Disease.
Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
[TBL] [Abstract][Full Text] [Related]
13. Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation.
Kim MO; Chawla P; Overland RP; Xia E; Sadri-Vakili G; Cha JH
J Neurosci; 2008 Apr; 28(15):3947-57. PubMed ID: 18400894
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.
Glajch KE; Sadri-Vakili G
J Huntingtons Dis; 2015; 4(1):1-15. PubMed ID: 25813218
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.
Jia H; Morris CD; Williams RM; Loring JF; Thomas EA
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):E56-64. PubMed ID: 25535382
[TBL] [Abstract][Full Text] [Related]
16. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
Schilling G; Savonenko AV; Coonfield ML; Morton JL; Vorovich E; Gale A; Neslon C; Chan N; Eaton M; Fromholt D; Ross CA; Borchelt DR
Exp Neurol; 2004 May; 187(1):137-49. PubMed ID: 15081595
[TBL] [Abstract][Full Text] [Related]
17. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.
Jia H; Kast RJ; Steffan JS; Thomas EA
Hum Mol Genet; 2012 Dec; 21(24):5280-93. PubMed ID: 22965876
[TBL] [Abstract][Full Text] [Related]
18. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death.
Roze E; Betuing S; Deyts C; Marcon E; Brami-Cherrier K; Pagès C; Humbert S; Mérienne K; Caboche J
FASEB J; 2008 Apr; 22(4):1083-93. PubMed ID: 18029446
[TBL] [Abstract][Full Text] [Related]
19. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.
Bobrowska A; Paganetti P; Matthias P; Bates GP
PLoS One; 2011; 6(6):e20696. PubMed ID: 21677773
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Sadri-Vakili G; Cha JH
Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
